Patients with chronic lymphocytic leukemia (CLL) bearing TP53 mutations experience chemorefractory disease and are therefore candidates for targeted therapy. However, the significance of low-burden TP53 mutations with <10% variant allele frequency (VAF) remains a matter for debate. Herein, we describe clonal evolution scenarios of low-burden TP53 mutations, the clinical impact of which we analyzed in a "real-world" CLL cohort. TP53 status was assessed by targeted next-generation sequencing (NGS) in 511 patients entering first-line treatment with chemo- and/or immunotherapy and 159 patients in relapse before treatment with targeted agents. Within the pretherapy cohort, 16% of patients carried low-burden TP53 mutations (0.1% to 10% VAF). Although their presence did not significantly shorten event-free survival after first-line therapy, it affected overall survival (OS). In a subgroup with TP53 mutations of 1% to 10% VAF, the impact on OS was observed only in patients with unmutated IGHV who had not received targeted therapy, as patients benefited from switching to targeted agents, regardless of initial TP53 mutational status. Analysis of the clonal evolution of low-burden TP53 mutations showed that the highest expansion rates were associated with fludarabine, cyclophosphamide, and rituximab regimen in both first- and second-line treatments (median VAF increase, 14.8× and 11.8×, respectively) in contrast to treatment with less intense treatment regimens (1.6×) and no treatment (0.8×). In the relapse cohort, 33% of patients carried low-burden TP53 mutations, which did not expand significantly upon targeted treatment (median VAF change, 1×). Sporadic cases of TP53 mutations' clonal shifts were connected with the development of resistance-associated mutations. Altogether, our data support the incorporation of low-burden TP53 variants in clinical decision making.

Center of Molecular Medicine Central European Institute of Technology Masaryk University Brno Czech Republic

Department of Internal Medicine Hematology and Oncology University Hospital Brno and Faculty of Medicine Masaryk University

000      

00000naa a2200000 a 4500

001      

bmc22011645

003      

CZ-PrNML

005      

20240103104834.0

007      

ta

008      

220425s2021 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1182/blood.2020009530 $2 doi

035    __

$a (PubMed)33945616

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Malcikova, Jitka $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000336506698

245    10

$a Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options / $c J. Malcikova, S. Pavlova, B. Kunt Vonkova, L. Radova, K. Plevova, J. Kotaskova, K. Pal, B. Dvorackova, M. Zenatova, J. Hynst, E. Ondrouskova, A. Panovska, Y. Brychtova, K. Zavacka, B. Tichy, N. Tom, J. Mayer, M. Doubek, S. Pospisilova

520    9_

$a Patients with chronic lymphocytic leukemia (CLL) bearing TP53 mutations experience chemorefractory disease and are therefore candidates for targeted therapy. However, the significance of low-burden TP53 mutations with 10% variant allele frequency (VAF) remains a matter for debate. Herein, we describe clonal evolution scenarios of low-burden TP53 mutations, the clinical impact of which we $a Patients with chronic lymphocytic leukemia CLL bearing TP53 mutations experience chemorefractory disease and are therefore candidates for targeted therapy However the significance of low burden TP53 mutations with $a Patients with chronic lymphocytic leukemia (CLL) bearing TP53 mutations experience chemorefractory disease and are therefore candidates for targeted therapy. However, the significance of low-burden TP53 mutations with <10% variant allele frequency (VAF) remains a matter for debate. Herein, we describe clonal evolution scenarios of low-burden TP53 mutations, the clinical impact of which we analyzed in a "real-world" CLL cohort. TP53 status was assessed by targeted next-generation sequencing (NGS) in 511 patients entering first-line treatment with chemo- and/or immunotherapy and 159 patients in relapse before treatment with targeted agents. Within the pretherapy cohort, 16% of patients carried low-burden TP53 mutations (0.1% to 10% VAF). Although their presence did not significantly shorten event-free survival after first-line therapy, it affected overall survival (OS). In a subgroup with TP53 mutations of 1% to 10% VAF, the impact on OS was observed only in patients with unmutated IGHV who had not received targeted therapy, as patients benefited from switching to targeted agents, regardless of initial TP53 mutational status. Analysis of the clonal evolution of low-burden TP53 mutations showed that the highest expansion rates were associated with fludarabine, cyclophosphamide, and rituximab regimen in both first- and second-line treatments (median VAF increase, 14.8× and 11.8×, respectively) in contrast to treatment with less intense treatment regimens (1.6×) and no treatment (0.8×). In the relapse cohort, 33% of patients carried low-burden TP53 mutations, which did not expand significantly upon targeted treatment (median VAF change, 1×). Sporadic cases of TP53 mutations' clonal shifts were connected with the development of resistance-associated mutations. Altogether, our data support the incorporation of low-burden TP53 variants in clinical decision making.

650    _2

$a dospělí $7 D000328

650    _2

$a senioři $7 D000368

650    _2

$a senioři nad 80 let $7 D000369

650    _2

$a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971

650    12

$a klonální evoluce $x účinky léků $7 D060965

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a lidé $7 D006801

650    _2

$a imunoterapie $7 D007167

650    _2

$a Kaplanův-Meierův odhad $7 D053208

650    _2

$a chronická lymfatická leukemie $x genetika $x terapie $7 D015451

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a mutace $x účinky léků $7 D009154

650    _2

$a nádorové buňky kultivované $7 D014407

650    _2

$a nádorový supresorový protein p53 $x genetika $7 D016159

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Kunt Vonková, Barbara $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000315289743 $7 xx0248649

700    1_

$a Radova, Lenka $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/000000018103148X

700    1_

$a Plevova, Karla $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000261488877 $7 xx0158852

700    1_

$a Kotaskova, Jana $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000316727346

700    1_

$a Pal, Karol $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000277264691

700    1_

$a Dvorackova, Barbara $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $1 https://orcid.org/0000000310858767

700    1_

$a Zenatova, Marcela $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $1 https://orcid.org/0000000238556085

700    1_

$a Hynst, Jakub $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/000000020079845X

700    1_

$a Ondrouskova, Eva $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $1 https://orcid.org/0000000308300692

700    1_

$a Panovska, Anna $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $1 https://orcid.org/0000000349553039

700    1_

$a Brychtova, Yvona $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $1 https://orcid.org/000000031038870X

700    1_

$a Zavacka, Kristyna $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/000000020753051X

700    1_

$a Tichý, Boris $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000192527974 $7 xx0312236

700    1_

$a Tom, Nikola $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000174400515

700    1_

$a Mayer, Jiri $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000305679887

700    1_

$a Doubek, Michael $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000212696282

700    1_

$a Pospisilova, Sarka $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000171362680

773    0_

$w MED00000807 $t Blood $x 1528-0020 $g Roč. 138, č. 25 (2021), s. 2670-2685

856    41

$u https://pubmed.ncbi.nlm.nih.gov/33945616 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20220425 $b ABA008

991    __

$a 20240103104829 $b ABA008

999    __

$a ok $b bmc $g 1789316 $s 1162843

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2021 $b 138 $c 25 $d 2670-2685 $e 20211223 $i 1528-0020 $m Blood $n Blood $x MED00000807

LZP    __

$a Pubmed-20220425